Shaperon Inc. Logo

Shaperon Inc.

Develops inflammasome inhibitors & nanobodies for inflammatory diseases and cancer.

378800 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
서울특별시 강남구 자곡로 174-10 강남에이스타워 606호(자곡동), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Shaperon Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for inflammatory diseases and cancer. The company specializes in creating innovative inflammasome inhibitors, utilizing a unique mechanism of action involving GPCR19-P2X7 modulation to suppress immune responses. Its development pipeline targets conditions such as atopic dermatitis and other immune-mediated inflammatory disorders. In addition to small molecules, Shaperon develops nanobody therapeutics for cancer immunotherapy, leveraging proprietary immunized libraries and high-throughput screening technologies. Founded in 2008, the company completed a successful initial public offering in October 2022.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Shaperon Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-16 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 86.0 KB
2025-09-16 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-09-16 00:00
Share Issue/Capital Change
유상증자1차발행가액결정 (주주배정후 실권주 일반공모)
Korean 7.6 KB
2025-09-16 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 40.4 KB
2025-09-16 00:00
Registration Form
[발행조건확정]증권신고서(지분증권)
Korean 435.2 KB
2025-09-16 00:00
Prospectus
투자설명서
Korean 2.7 MB
2025-09-16 00:00
Share Issue/Capital Change
권리락 (유상증자)
Korean 3.5 KB
2025-09-12 00:00
Director's Dealing
임원ㆍ주요주주특정증권등거래계획보고서
Korean 42.6 KB
2025-09-01 00:00
Registration Form
[기재정정]증권신고서(지분증권) (2025.10)
Korean 3.2 MB
2025-08-18 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 32.0 KB
2025-08-18 00:00
Registration Form
증권신고서(지분증권) (2025.10)
Korean 2.5 MB

Automate Your Workflow. Get a real-time feed of all Shaperon Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Shaperon Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
GENOLUTION INC. Logo
Develops molecular diagnostic and RNAi solutions for genetic testing and life sciences research.
South Korea 225220
Genome&Company Logo
Clinical-stage biopharma developing cancer therapies using microbiome, immune inhibitors, and ADCs.
South Korea 314130
Develops molecular diagnostics using DNA methylation biomarkers for early cancer detection.
South Korea 228760
Genomtec S.A. Logo
Develops a mobile platform for rapid, precise genetic diagnostics at the point-of-care.
Poland GMT
GENOTECH CORP. Logo
A biotech firm offering gene synthesis, genome analysis, and biopharmaceutical products globally.
South Korea 066830
Gentian Diagnostics ASA Logo
Develops & manufactures IVD immunoassays for human & veterinary disease diagnostics.
Norway GENT
GI Innovation Inc. Logo
Develops fusion protein biologics for oncology, allergic, and metabolic diseases.
South Korea 358570
GlaxoSmithKline PLC Logo
A biopharmaceutical company developing vaccines and specialty medicines to prevent and treat disease.
United Kingdom GSK
GL Pharm Tech Corp. Logo
Develops improved drugs and generics, and licenses proprietary drug formulation technologies.
South Korea 204840
GNI  Group Ltd. Logo
Biopharma firm developing novel drugs for cancer and inflammatory diseases using genetics.
Japan 2160

Talk to a Data Expert

Have a question? We'll get back to you promptly.